Literature DB >> 24300003

Extremely low-frequency pulsed magnetic fields and multiple sclerosis: effects on neurotransmission alone or also on immunomodulation? Building a working hypothesis.

F Bistolfi1.   

Abstract

This paper outlines the current state of knowledge on the pathology and treatment of multiple sclerosis (MS) and critically analyses the vast clinical experience of Sandyk in the use of pulsed magnetic fields of 5 Hz at 7.5 pT to treat many symptoms of MS. A complete regression of symptoms, or at least a major improvement, is sometimes so rapid as to suggest that ELF fields exert a greater effect on axonal and synaptic neurotransmission than on the processes leading to demyelination. Pulsed magnetic fields of 50-100 Hz and a few mT (whose flux intensity is 10(9) times greater than that of the fields used by Sandyk) have been seen to induce profound morphological changes (the Marinozzi effect) in the plasma membrane of several cell types, including Raji human lymphoblastoid cells. These observations underlie the author's hypothesis on the possible use of such fields in the treatment of MS. Indeed, these fields should induce the functional arrest of the cells (B- and T-lymphocytes, macrophages, microglia, dendritic cells) of the MS plaque, thereby providing an "electromagnetic immunomodulatory boost" to the effects of drug therapy. To test this working hypothesis, it is suggested that preliminary experimental research be carried out to ascertain: 1) the Marinozzi effect in vivo; 2) the Marinozzi effect on microglia and dendritic cells; and 3) the duration of the membrane changes and their relaxation rate. ELF magnetic fields in the picotesla and millitesla ranges are aimed at improving neurotransmission and correcting local immune pathology, respectively. Both types of field might find application in the treatment of MS patients who no longer respond to or tolerate currently used drugs.

Entities:  

Year:  2007        PMID: 24300003     DOI: 10.1177/197140090702000612

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  6 in total

Review 1.  Pain in Osteoporosis: From Pathophysiology to Therapeutic Approach.

Authors:  Antonino Catalano; Gabriella Martino; Nunziata Morabito; Claudia Scarcella; Agostino Gaudio; Giorgio Basile; Antonino Lasco
Journal:  Drugs Aging       Date:  2017-10       Impact factor: 3.923

2.  Electromagnetic field stimulation potentiates endogenous myelin repair by recruiting subventricular neural stem cells in an experimental model of white matter demyelination.

Authors:  Mohammad Amin Sherafat; Motahareh Heibatollahi; Somayeh Mongabadi; Fatemeh Moradi; Mohammad Javan; Abolhassan Ahmadiani
Journal:  J Mol Neurosci       Date:  2012-05-17       Impact factor: 3.444

Review 3.  Extremely low frequency electromagnetic fields stimulation modulates autoimmunity and immune responses: a possible immuno-modulatory therapeutic effect in neurodegenerative diseases.

Authors:  Fabio Guerriero; Giovanni Ricevuti
Journal:  Neural Regen Res       Date:  2016-12       Impact factor: 5.135

4.  Efficacy of dietary supplement with nutraceutical composed combined with extremely-low-frequency electromagnetic fields in carpal tunnel syndrome.

Authors:  Teresa Paolucci; Giulia Piccinini; Sveva Maria Nusca; Gabriella Marsilli; Alice Mannocci; Giuseppe La Torre; Vincenzo Maria Saraceni; Maria Chiara Vulpiani; Ciro Villani
Journal:  J Phys Ther Sci       Date:  2018-06-12

Review 5.  Electromagnetic Field Therapy: A Rehabilitative Perspective in the Management of Musculoskeletal Pain - A Systematic Review.

Authors:  Teresa Paolucci; Letizia Pezzi; Antonello Marco Centra; Niki Giannandrea; Rosa Grazia Bellomo; Raoul Saggini
Journal:  J Pain Res       Date:  2020-06-12       Impact factor: 3.133

6.  Low frequency magnetic fields enhance antitumor immune response against mouse H22 hepatocellular carcinoma.

Authors:  Yunzhong Nie; Yueqiu Chen; Yongbin Mou; Leihua Weng; Zhenjun Xu; Youwei Du; Wenmei Wang; Yayi Hou; Tingting Wang
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.